ArticlePloS one2020

DLX1008 (brolucizumab), a single-chain anti-VEGF-A antibody fragment with low picomolar affinity, leads to tumor involution in an in vivo model of Kaposi Sarcoma.

Anthony B Eason et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.